MXCT · MaxCyte, Inc.

MaxCyte’s Q1 2026 results reflect a bifurcated performance: core business revenue declined 25% year-over-year to $6.2 million, driven by lower instrument sales (-7%), significant contraction in PAs and consumables (-41%), and reduced license revenue (-17%), suggesting near-term pressure on recurring hardware and consumable demand. In contrast, SPL Program-related revenue rose 62% to $3.4 million, fueled by milestone payments (+50%) and royalties (+200%), underscoring clinical progression among SPL partners—including one that initiated dosing in a registrational study during the quarter. Gross margin held at 84% (down 200 bps YoY), though non-GAAP adjusted gross margin—excluding SPL revenue and excess/obsolete inventory reserves—fell 500 bps to 78%, indicating margin pressure from inventory adjustments and SPL revenue’s lower-margin nature. A sharp 33% reduction in operating expenses ($14.3M vs $21.2M) drove meaningful improvement in bottom-line metrics: net loss narrowed by $5.5M and EBITDA loss improved by $6.1M, aided by lower stock-based compensation ($1.1M vs $3.0M). Management reaffirmed full-year guidance, emphasizing confidence in SPL pipeline advancement—including expected Phase 3 initiations—and highlighted strategic capital allocation via the new $10M share repurchase program, which does not constrain investment in growth initiatives like ExPERT DTx and SeQure Dx integration. With $147.7M in cash and investments as of March 31, 2026, and a projected minimum of $136M year-end cash balance (excluding buyback spend), MaxCyte retains substantial financial flexibility to fund operations, invest in platform expansion, and return capital—reinforcing its positioning as an enabling infrastructure provider amid accelerating ex vivo cell therapy development.